Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT01336933


This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

Official Title

A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin Lymphoma

Stanford Investigator(s)

Ranjana Advani
Ranjana Advani

Saul A. Rosenberg, MD, Professor of Lymphoma

Lauren Maeda
Lauren Maeda

Clinical Associate Professor, Medicine - Oncology


Inclusion Criteria:

   - Histologically confirmed new diagnosis of Stage II, III and IV peripheral T-cell NHL
   not otherwise specified (NOS), anaplastic large cell lymphoma (ALK negative) (ALK
   positive if international prognostic index [IPI] 3, 4, or 5), angioimmunoblastic
   T-cell lymphoma, enteropathy associated T-cell lymphoma, hepatosplenic gamma delta
   T-cell lymphoma

   - Pathology material (hematoxylin and eosin [H&E] stain, immunohistochemistry [IHC] and
   pathology report from initial diagnosis, if slides are not available, then 8 unstained
   slides of 4 micron thickness or a representative block should be sent) will be
   reviewed, and the diagnosis confirmed by University Nebraska Medical Center (UNMC)
   pathology department (retrospective diagnostic review: treatment may commence prior to
   the UNMC review)

   - No prior therapy with the exception of prior radiation therapy and 1 cycle of
   chemotherapy based on current diagnosis and clinical condition

   - Age 19 years or older (the age of consent in Nebraska); age 18 years or older
   (applicable to states where the age of majority is 18)

   - Expected survival duration of >= six months

   - Karnofsky Performance Status >= 70

   - Absolute neutrophil count (ANC) >= 1000 cells/mm^3, unless due to lymphoma involvement
   of the bone marrow

   - Platelet Count >= 100 mm^3, unless due to lymphoma involvement of the bone marrow

   - Total bilirubin =< 1.5 x upper normal limit (ULN), or =< 3 x ULN if documented hepatic
   involvement with lymphoma, or =< 5 x ULN if history of Gilbert's Disease

   - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5
   x ULN if documented hepatic involvement with lymphoma)

   - Serum potassium within normal range

   - Serum creatinine < 2.0 mg/dL or calculated creatinine clearance (CrCl) > 45 mL/min

   - Prothrombin time (PT) or international normalized ratio (INR), and partial
   thromboplastin time (PTT) =< 1.5 x ULN unless patient is receiving anticoagulants; if
   patient is on anticoagulation therapy, levels should be within therapeutic range

   - Patients with measurable disease; patients with non-measurable but evaluable disease
   may be eligible after discussion with the principal investigator (PI); baseline
   measurements and evaluations must be obtained within 6 weeks of registration to the
   study; abnormal positron emission tomography (PET) scans will not constitute evaluable
   disease, unless verified by computed tomography (CT) scan or other appropriate imaging

   - Patients with measurable disease must have at least one objective measurable disease
   parameter; a clearly defined, bidimensionally measurable defect or mass measuring at
   least 2 cm in diameter on a CT scan will constitute measurable disease; proof of
   lymphoma in the liver is required by a confirmation biopsy

   - Women must not be pregnant or breast-feeding due to teratogenic effects of

      - All females of childbearing potential must have a blood test within 2 weeks prior
      to registration to rule out pregnancy

      - Pregnancy testing is not required for post-menopausal or surgically sterilized

   - Male and female patients of reproductive potential must agree follow accepted birth
   control measures

   - Patient must be able to adhere to the study visit schedule and other protocol

   - Patients must be willing to give written informed consent, and sign an institutionally
   approved consent form before performance of any study-related procedure not part of
   normal medical care; with the exception of 1 cycle of chemotherapy based on current
   diagnosis and clinical condition, with the understanding that consent may be withdrawn
   by the subject at any time without prejudice to future medical care

   - No serious disease or condition that, in the opinion of the investigator, would
   compromise the patient's ability to participate in the study

Exclusion Criteria:

   - Pregnant or breast feeding females

   - Known positive for human immunodeficiency virus (HIV), human T-lymphotropic virus type
   1 (HTLV-1), or infectious hepatitis, type A, B or C or active hepatitis

   - Major surgery within 2 weeks of study drug administration

   - Prior malignancies within the past 3 years with exception of adequately treated basal
   cell, squamous cell skin cancer, or thyroid cancer; carcinoma in situ of the cervix or
   breast; prostate cancer of Gleason Grade 6 or less with stable prostate-specific
   antigen (PSA) levels

   - Patients with a diagnosis of other peripheral T-cell lymphoma (PTCL) histologies other
   than those specified in the inclusion criteria

   - Contraindication to any of the required concomitant drugs or supportive treatments,
   including hypersensitivity to all anticoagulation and antiplatelet options, antiviral
   drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment

   - Any other clinically significant medical disease or condition laboratory abnormality
   or psychiatric illness that, in the Investigator's opinion, may interfere with
   protocol adherence or a subject's ability to give informed consent

   - Concomitant administration of nonsteroidal anti-inflammatory drugs (NSAIDs) and
   trimethoprim/sulfamethoxazole will not be allowed, since these may result in delayed
   clearance of pralatrexate


drug: cyclophosphamide

other: laboratory biomarker analysis

genetic: comparative genomic hybridization

genetic: gene expression analysis

genetic: nucleic acid sequencing

genetic: mutation analysis

other: immunohistochemistry staining method

genetic: microarray analysis

genetic: RNA analysis

drug: Pralatrexate

drug: Etoposide

drug: Prednisone

drug: Vincristine

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts